bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.03.25.714158

Antisense lncRNA transcription promotes A-to-I RNA editing via intermolecular dsRNA in breast cancer

Abstract

A-to-I RNA editing, catalysed by ADAR enzymes, is the most prevalent post-transcriptional RNA modification in mammals, yet the regulatory inputs shaping cell-type-specific editomes remain incompletely understood. Here we characterise over 2.2 million unique A-to-I editing sites across MCF7 (ER+) and MDA-MB-231 (triple-negative) breast cancer cell lines and 117 patient tumours. MCF7 exhibited substantially more editing per sample, driven by higher ADAR1 expression and a shifted ADAR1/ADAR2 ratio that favoured broad intronic Alu editing in the luminal line versus site-selective synonymous coding editing in the aggressive line. Despite this divergence, approximately 2,500 sites were constitutively edited in both cell lines, defining a conserved core editome. We demonstrate that natural antisense lncRNA transcription constitutes an independent, additive pathway for editing through intermolecular dsRNA formation: editing density at sense-antisense overlaps reversed from depletion to enrichment as a function of balanced co-expression, antisense overlap increased editing probability without affecting density among edited genes, and a factorial analysis across all expressed genes established that inverted Alu pairs are the dominant editing substrate while antisense lncRNA transcription provides an independent contribution whose magnitude scales with overlap length and Alu content. Experimental validation at the NDUFS1/NDUFS1-AS1 locus confirmed co-expression of sense and antisense transcripts, verified editing at computationally predicted positions by Sanger sequencing with genomic DNA controls, and demonstrated differential editing and expression between cell lines. Differentially edited genes included the oncogene VOPP1 and fatty acid metabolism genes at antisense loci, linking epitranscriptomic regulation to the lipid metabolic phenotype of aggressive breast cancer. Our findings establish a two-tier model: a dominant ADAR1-driven programme targeting intramolecular Alu dsRNA, upon which an independent lncRNA antisense pathway is superimposed via intermolecular dsRNA, jointly producing subtype-specific editing landscapes that preserve a constitutive core but diverge in magnitude, functional distribution, and site selection.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Samorowska, K., Wanowska, E., Szczesniak, M. W.. 2026-03-27. Antisense lncRNA transcription promotes A-to-I RNA editing via intermolecular dsRNA in breast cancer. https://doi.org/10.64898/2026.03.25.714158

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗